NASDAQ: ACTUActuate Therapeutics Inc Stock
$9.20+0.04 (+0.44%)
Updated Apr 30, 2025
ACTU Price
$9.20
Fair Value Price
$1.03
Market Cap
$179.69M
52 Week Low
$5.51
52 Week High
$11.73
P/E
-2.82x
P/B
1,724.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
88.44
Operating Cash Flow
-$22M
Beta
0.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACTU Overview
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACTU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACTU
Ranked#177 of 462
Ranked#177 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ACTU news, forecast changes, insider trades & much more!
ACTU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACTU ($9.20) is overvalued by 791.37% relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACTU ($9.20) is not significantly undervalued (791.37%) relative to our estimate of its Fair Value price of $1.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACTU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACTU due diligence checks available for Premium users.
Valuation
ACTU fair value
Fair Value of ACTU stock based on Discounted Cash Flow (DCF)
Price
$9.20
Fair Value
$1.03
Overvalued by
791.37%
ACTU ($9.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACTU ($9.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACTU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACTU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.82x
Industry
-162.28x
Market
29.18x
ACTU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1,724.71x
Industry
4.45x
ACTU is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACTU's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.4M
Profit Margin
0%
ACTU's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.3M
Liabilities
$9.2M
Debt to equity
88.44
ACTU's short-term assets ($9.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACTU's short-term assets ($9.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$0.0
Financing
-$109.4k
ACTU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACTU vs Biotech Stocks
Actuate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.